MedTrace Logo

Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive

NCT02470650 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2025-07-30

No results posted yet for this study

Summary

The main objective of this study is to know the efficiency (costeffectiveness) at 48 weeks of initiation of antiretroviral treatment. three strategies of treatment.

Conditions

  • Patient Compliance
  • Antiretroviral Therapy Intolerance

Interventions

DRUG

elvitegravir/cobicistat/emtricitabine/tenofovir

1 recovered tablet once Per day ● Specify total dose (number and unit): 150 mg de elvitegravir, 150 mg cobicistat, 200 mg emtricitabine , 245 mg tenofovir disoprox milligram(s)

DRUG

Darunavir

Darunavir 800 mg (Prezista®) 1 recovered tablet 800 mg once a day

DRUG

abacavir/lamivudine

Abacavir 600 mg /lamivudine 300 mg recovered tablet once a day

DRUG

Ritonavir

Ritonavir 100 mg recovered tablet once a day

DRUG

Lamivudine

lamivudine 300mg (Epivir) 1 recovered tablet

DRUG

rilpivirine

rilpivirine (Edurant®) 1 recovered tablet 25 mg. once a day

Sponsors & Collaborators

  • Juan A. Arnaiz

    lead OTHER

Principal Investigators

  • Mallolas · Hospital Clínic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2017-07-31
Completion
2017-10-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02470650 on ClinicalTrials.gov